Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients

Kim, M.K.; Suh, Cheolwon; Lee, D.H.; Min, Chang Ki; Kim, Seung Ju; Kim, K.; Moon, Joon-Ho; Yoon, Sung Soo; Lee, G.-W.; Kang, Hye Jin; Kim, S.-H.; Choi, Chul Won; Eom, Hyeon Seok; Kwak, Jae‐Yong; Kim, H.J.; Mun, Yeung Chul; Bang, Soo Mee; Lee, K.; Shin, Ho-Jin; Lee, J.H.

doi:10.1093/annonc/mdq393

Cited by 46 publications

(47 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…67% of patients had stage 3 or higher stage disease. [7][8][9] Our case is different from other cases in the literature with having no symptoms except fatigue and widespread body pain and being older than other cases.…”

Section: Discussioncontrasting

confidence: 83%

Immunoglobulin D Multiple Myeloma, A Rare Myeloma Type in Elder Patients: Case Report

Yavuzer¹,

Erçalışkan²,

Yadigar³

et al. 2016

Turkiye Klinikleri J Intern Med

View full text Add to dashboard Cite

ultiple myeloma is a malignant disease originating from differentiated plasma cells. It is the second most common haematologic neoplasia and especially seen in elder population. 35% of myeloma patients are under 65 years old, 28% are between 65-74 years old, 37% are over 75 years old. IgD Multiple Myeloma (IgD-MM) is a rare type of myelomas (1%), more common in male gender and usually diagnoses at under 65 years old. A An na ah h t ta ar r K Ke e l li i m me e l le er r: : Multipl miyelom; immunglobulin delta-zincirler; yaşlı T Tu ur r k ki i y ye e K Kl li i n ni ik k l le e r ri i J J I In nt te er rn n M Me ed d 2 20 01 16 6; ;1 1( (2 2) ):

show abstract

Section: Discussioncontrasting

confidence: 83%

Immunoglobulin D Multiple Myeloma, A Rare Myeloma Type in Elder Patients: Case Report

Yavuzer¹,

Erçalışkan²,

Yadigar³

et al. 2016

Turkiye Klinikleri J Intern Med

View full text Add to dashboard Cite

show abstract

“…Five studies, each including at least 20 patients with IgD-associated multiple myeloma, have been published to date. [1][2][3][4][5] This entity appears to have clinical differences compared with non-IgD myeloma, including a younger age at disease presentation and a higher incidence of extramedullary disease. Some have suggested that patients with IgD myeloma have a greater degree of renal insufficiency at presentation.…”

Section: Introductionmentioning

confidence: 99%

Immunoglobulin D amyloidosis: a distinct entity

Gertz¹,

Buadi²,

Hayman³

et al. 2012

Blood

View full text Add to dashboard Cite

“…This is a rare entity with very low incidence that accounts for less than 2% of total MM cases and it is characterized to have poor prognosis; the median survival time is 12 months following diagnosis [3] or at most, two years [4]. In the clinical characteristic of IgD MM patients, Kim et al found a younger age at time of presentation with advanced stage and a more aggressive clinical course [5]. In a cases series of 53 patients with IgD MM described by Blade et al, they reported the main presenting features were bone pain (72%), fatigue (36%), renal function impairment (33%), weight loss (32%), hypercalcemia (22%), extramedullary plasmacytomas (19%) and associated amyloidosis (19%) [6].…”

Section: Discussionmentioning

confidence: 99%

A Challenging Case of IgD Kappa Multiple Myeloma Associated With Primary Amyloidosis: Importance of Serum Free Light Chains in Monitoring Treatment Response and Disease Relapse

Silva¹,

Guitarte²,

Valladares³

et al. 2014

J Leuk

View full text Add to dashboard Cite

Multiple Myeloma (MM) is a malignancy of B cells characterized by an atypical proliferation of plasma cells. IgD MM has a very low incidence (2% of total MM cases) and it´s characterized by an aggressive course and a worse prognosis than other subtypes. The serum free light chains (sFLC) are very important markers for monitoring patients with MM and other monoclonal gammopathies. When the sFLC are present in low concentrations, it is often difficult to detect them by conventional methods such as serum protein electrophoresis and serum immunofixation. This case is a good example of the utility of sFLC in the monitoring of treatment and relapse of patients with MM. The sFLC determinations detected when chemotherapy applied was not being completely effective and it predicted a relapse before new clinical findings were present. We report the rare case of a patient diagnosed of IgD MM with associated light chain kappa Primary (AL) Amyloidosis and characterized by clinical findings of very bad prognosis (high levels of sFLC kappa at diagnosis, high renal impairment and subsequent development of intracranial plasmacytoma), aggressive course and refractory to several lines of treatment.

show abstract

Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients

Abstract: IgD MM is an aggressive disease that is usually detected at an advanced stage. Despite a positive initial response, survival after relapse was dismal. Intensive treatment strategies before and following stem cell transplantation may improve outcomes in younger patients.

Cited by 46 publications

References 19 publications

Immunoglobulin D Multiple Myeloma, A Rare Myeloma Type in Elder Patients: Case Report

Immunoglobulin D Multiple Myeloma, A Rare Myeloma Type in Elder Patients: Case Report

Immunoglobulin D amyloidosis: a distinct entity

A Challenging Case of IgD Kappa Multiple Myeloma Associated With Primary Amyloidosis: Importance of Serum Free Light Chains in Monitoring Treatment Response and Disease Relapse

Contact Info

Product

Resources

About